Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Introduction This multicenter, open-label, phase II study was carried out to compare the efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface integrins αVβ3 and αVβ5, with that of docetaxel in patients with advanced non-small-cell lung cancer (NSCLC). Methods Pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Manegold, Christian, Vansteenkiste, Johan, Cardenal, Felipe, Schuette, Wolfgang, Woll, Penella J., Ulsperger, Ernst, Kerber, Anne, Eckmayr, Josef, von Pawel, Joachim
Format: Artigo
Language:Inglês
Published: Springer US 2012
Subjects:
Phase II Studies
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553405/
https://ncbi.nlm.nih.gov/pubmed/22752690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9842-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items